Source: Heart Future; Editor: Jessi
Reprint Requirements: If the source of the article is indicated at the beginning of the text, it can be reprinted directly.Recently,Jiangsu Trulive Medtech Co., Ltd.(hereinafter referred to as "Trulive"）AnnouncedSuccessfully Completed B+ Round FinancingThis round of financing was led by Xiamen High-Tech Investment and Yixing Jiayi. The funds will be used to accelerate the development of Trulive.TheProduct Development and Market Promotion，Further solidify its leading position in the field of structural heart disease treatment.。It is worth mentioning that TruliveCompleted a round of financing exceeding 100 million yuan in May this year, this B+ round of financing once again demonstrates the high recognition from investment institutions of its technical strength and market prospects. This fund willAccelerate the subsequent clinical process of the company's core products,At the same time, it injects new vitality into the development of the structural heart disease field in China.Trulive focuses onStructural Heart Disease Treatment`, and in`ChinaEndovascular Valve Intervention Technology FieldIn a leading position.Although there is a certain gap compared to the United States and Europe, its development speed is extremely rapid.Currently, the company hasSeven core products are being advanced simultaneously., among which3 products have entered the clinical stage。Trulive possessesStent、PericardiumAndCatheterThree major integrated technology platforms, with a layout in transcatheter mitral valve, tricuspid valve, aortic valve replacement products, and full-range repair products.BecomeThe First in ChinaFull Layout in Four Major Golden Tracks with Substantial Progress in Core ProductsChinese companies.
▲ Company Financing History# Structural Heart Disease Treatment MarketIt is understood that structural heart disease mainly includes congenital heart disease, valvular heart disease, cardiomyopathy, and great vessel diseases, posing a serious threat to residents' health. The incidence rate and the number of patients are still increasing. In recent years, interventional treatment for structural heart disease has become a major hotspot in global cardiovascular intervention.The scientific and effective prevention and treatment of structural heart disease have become an urgent clinical issue to be addressed., whose diagnosis and treatment has also become a major hotspot and new direction in the global cardiology field.InHigh-End Market for Structural Heart Disease，The market share is mainly occupied by foreign medical giants.For example, Edwards Lifesciences holds nearly 70% of the global valve market share, almost dominating this field. Although the Chinese market has developed rapidly in recent years, it is still in its early stages overall, with enormous growth potential and demand space.The global interventional medical device market for structural heart disease has experienced rapid growth, with sales revenue increasing from USD 4.8 billion in 2017 to USD 9.3 billion in 2021, at a compound annual growth rate (CAGR) of 18.0%.And is expected to reach USD 19.8 billion by 2025, with a compound annual growth rate of 20.8% from 2021 to 2025.。In China, in line withNumber of Patients with Structural Heart Disease Suitable for Interventional TreatmentIncreased from approximately 4.8 million in 2017 to about 5.3 million in 2021,And is expected to reach approximately 6 million by 2025.。The Market Size of Interventional Medical Devices for Structural Heart Disease in ChinaIncreased from RMB 400 million in 2017 to RMB 2 billion in 2021, with a compound annual growth rate of 48.3%,And is expected to reach RMB 10.4 billion by 2025, with a compound annual growth rate of 51.0% from 2021 to 2025.。The treatment methods for structural heart disease mainly include medication, surgical treatment, and interventional procedures. Among them,Interventional TherapyHas become one of the most important treatment methods for structural heart disease., with the advantages of minimal trauma, low risk, fewer complications, and a short hospital stay,Gradually replaced traditional open-chest surgery。Specifically, the interventional treatment of structural heart disease is mainly divided into the following directions:- Traditional interventional therapy: This is the earliest interventional treatment method, mainly used for the correction of congenital heart disease, such as atrial septal defect, ventricular septal defect, patent ductus arteriosus, etc.
- Transcatheter Left Atrial Appendage Closure：This technology is mainly used to prevent stroke in patients with atrial fibrillation by reducing thrombus formation through the occlusion of the left atrial appendage.
- Percutaneous Left Ventricular Reconstruction: This technique is used to treat certain specific cardiac structural abnormalities, such as ventricular remodeling in patients with dilated cardiomyopathy or heart failure.
- Transcatheter Heart Valve Therapy: In recent years,Transcatheter Aortic Valve Replacement(Transcatheter Aortic Valve Replacement, TAVR) andTranscatheter Mitral Valve Edge-to-Edge Repair(Transcatheter Edge-to-Edge Repair, TEER) and other technologies have made significant progress,And has gradually become the preferred treatment method for mitral valve and aortic valve diseases.。
The Market Size of Structural Heart Disease is Huge, especially the number of patients with mitral regurgitation and tricuspid regurgitation is relatively high,Market potential is much greater than traditional TAVI(Transcatheter Aortic Valve Implantation).According to Edwards Lifesciences' estimates, the market size for transcatheter mitral and tricuspid valve disease treatment devices is expected to reach $3 billion in 2024.With the rise in the incidence of heart disease, increased public awareness, and growing acceptance of interventional medical solutions,The interventional device market has ushered in vast demand space.。Trulive has a significant competitive advantage and development potential in the field of structural heart disease through comprehensive layout and technological innovation.While building a "large and comprehensive" full product line in the valve field, it also targets the "small and beautiful" markets of heart failure, peripheral, and other interventional non-implantable fields.By supplementing with easy-to-operate yet high-performance pipelines to quickly achieve revenue breakthroughs for enterprises, allowing "comprehensive and large-scale" and "small but beautiful" product lines to complement each other,Strengthen the company's product portfolio and enhance its self-sustaining capabilities., comprehensively promoting the coordinated development of the company's entire product line.Trulive has already achievedStent, Pericardium, CatheterThree major comprehensive technology platforms, fully covering heart valve diseases,Heart failure, peripheral, and coronary artery diseases，Covering multiple cardiovascular billion-dollar tracks。ItsCardiovascular TreatmentThe one-stop toolbox can effectively address issues such as heart valve disease, intravascular stenosis or occlusion, and heart failure, ensuring the proper flow of blood.
Each product from Trulive undergoes extremely rigorous极限 testing, such as heart valve replacement products that must endure hundreds of millions of fatigue cycles in vitro to ensure their safety and effectiveness.In the field of cardiovascular diseases, Trulive has accumulated a large number of core technologies with strong innovation, high practicality, and independent intellectual property rights. As of now,The company has applied for more than 200 patents in total., 80% of which are invention patents, and more than 40 are PCT international patents.The Neo Series Transcatheter Valve Repair System of the CompanyYesThe First in ChinaProducts that have entered the large-scale clinical stage and achieved the ability of one sheath with two valves, canSimultaneously applied to mitral and tricuspid valve repair treatments。ThisThe development of these technologies and products not only meets the demands of the Chinese market but also provides new treatment options for patients worldwide.。
Trulive was founded in 2019 and isThe only one in ChinaA cardiovascular interventional platform enterprise specializing in solving blood flow direction issues, committed to developing product technologies that better align with the anatomical and pathological characteristics of Chinese patients.
The one-stop toolbox for cardiovascular treatment developed by the company provides solutions for various blood flow issues in cardiovascular diseases, includingValve Management——Treatment of heart valve disease, regulating the correct flow of blood;Dredge——Treatment of vascular stenosis or embolism to ensure smooth blood flow;Shunt——Intervention for heart failure, relieving pathological hypertension.
The company has been awarded "Top 50 Most Investment-worthy in Healthcare 2023" due to its outstanding technological innovation, forward-thinking business strategies, steady corporate operations, and excellent capital market performance. Mr. Wen Jing, Chairman of the company, stated that in the future, Trulive will continue to advance the localization of high-end medical devices in China, enabling more doctors and patients to benefit from domestically produced high-end interventional medical devices.
